Advanced non-small-cell lung cancer: how to manage EGFR and HER2 exon 20 insertion mutation-positive disease

EGFR exon 20 insertion mutations (Ex20ins) and HER2 mutations characterize an oncogene-addicted subtype of non-small-cell lung cancer (NSCLC) typically associated with a never or light smoking history, female sex, and adenocarcinoma histology. Nevertheless, Ex20ins-mutant and HER2-mutant advanced NS...

Ful tanımlama

Kaydedildi:

Detaylı Bibliyografya
Asıl Yazarlar:	Giulio Metro, Andrea De Giglio, Biagio Ricciuti, Marco Siringo, Daniele Marinelli, Alain Gelibter, Federica Pecci, Rossana Berardi, Luca Cantini, Alessandro Di Federico, Elisa Andrini, Mirta Mosca, Giuseppe Lamberti, Marta Brambilla, Giannis Mountzios
Materyal Türü:	Artigo
Dil:	Inglês
Baskı/Yayın Bilgisi:	BioExcel Publishing Ltd 2022-07-01
Seri Bilgileri:	Drugs in Context
Konular:	amivantamab egfr exon 20 insertion mutations her2 mutation mobocertinib non-small-cell lung cancer poziotinib trastuzumab deruxtecan
Online Erişim:	https://www.drugsincontext.com/advanced-non-small-cell-lung-cancer-how-to-manage-egfr-and-her2-exon-20-insertion-mutation-positive-disease
Etiketler:	Etiketle Etiket eklenmemiş, İlk siz ekleyin!

Advanced non-small-cell lung cancer: how to manage EGFR and HER2 exon 20 insertion mutation-positive disease

Benzer Materyaller